首页> 外文OA文献 >Ex Vivo Expansion of Human Mesenchymal Stem Cells in Defined Serum-Free Media
【2h】

Ex Vivo Expansion of Human Mesenchymal Stem Cells in Defined Serum-Free Media

机译:人间充质干细胞在无血清培养基中的体外扩增

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and allogeneic hMSCs appear to be safe; however, efficacy has not been demonstrated in recent late-stage clinical trials. Optimized cell bioprocessing protocols may enhance the efficacy as well as safety of hMSC therapeutics. Classical media used for generating hMSCs are typically supplemented with ill-defined supplements such as fetal bovine serum (FBS) or human-sourced alternatives. Ideally, culture media are desired to have well-defined serum-free formulations that support the efficient production of hMSCs while maintaining their therapeutic and differentiation capacity. Towards this objective, we review here current cell culture media for hMSCs and discuss medium development strategies.
机译:目前正在评估人间充质干细胞(hMSCs)在临床研究中的治疗潜力,以治疗各种疾病,病症和损伤。迄今为止,早期研究表明,使用自体和同种异体hMSC似乎是安全的。然而,在最近的后期临床试验中尚未证明疗效。优化的细胞生物处理方案可以增强hMSC治疗药物的功效和安全性。用于生成hMSC的经典培养基通常会添加不明确的补充剂,例如胎牛血清(FBS)或人类来源的替代品。理想地,期望培养基具有定义明确的无血清制剂,该制剂支持hMSC的有效生产,同时保持其治疗和分化能力。为了实现这一目标,我们在这里回顾了hMSCs的当前细胞培养基,并讨论了培养基开发策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号